Menu Search
Equities

Transgene SA

TGNA:BER

Transgene SA

Actions
  • Price (EUR)0.822
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change-42.60%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

  • Revenue in EUR (TTM)6.22m
  • Net income in EUR-22.91m
  • Incorporated1979
  • Employees162.00
  • Location
    Transgene SA400 Boulevard Gonthier d'AndernachParc d'Innovation - CS80166ILLKIRCH-GRAFFENSTADEN 67405FranceFRA
  • Phone+33 388279100
  • Fax+33 388279111
  • Websitehttps://www.transgene.fr
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.